Metastatic Profiles and Survival Differences Between Infiltrating Ductal Carcinoma and Infiltrating Lobular Carcinoma in Invasive Breast Cancer.

BACKGROUND: In this study, we conducted a comprehensive evaluation of metastatic profiles and survival outcomes in patients with infiltrating ductal carcinoma (IDC) and infiltrating lobular carcinoma (ILC) treated at our university hospital center.

METHODS: We collected and analyzed data from all patients diagnosed with invasive breast cancer at our center between January 1, 2007, and 31 December, 2014. We specifically compared three subgroups: patients with IDC, patients with ILC and patients with mixed carcinoma, which is a combination of IDC and ILC.

RESULTS: Among the 1963 patients treated for invasive breast cancer in our center during the study period, 1435 had IDC, 466 had ILC, and 59 had mixed carcinoma. The incidence of patients with at least one positive axillary lymph node differed significantly: 40% for IDC, 36% for ILC, and 45% for mixed carcinoma (p=0.001). However, there was no significant difference in the mean number of positive nodes (p=0.1633). The occurrence of distant metastases was lower in patients with ILC (p=0.04), particularly in the case of brain metastases (p=0.01), although there was no difference in bone or visceral metastatic sites. Patients with ILC exhibited a longer mean time to metastasis from the initial diagnosis of invasive breast carcinoma. Overall survival (p=0.0525) and survival without locoregional recurrence (p=0.026) were significantly different. Specifically, the 5-year overall survival rates for IDC, ILC, and mixed carcinoma were approximately 95%. Distance metastatic-free survival at 5 years was 85% for IDC, 91% for ILC, and 87% for mixed carcinoma (p=0.00506).

CONCLUSION: Our findings indicate variations in the distribution of distant metastatic sites among patients with IDC, ILC, and mixed carcinoma, as well as differences in survival outcomes. This study sheds light on the unique characteristics and clinical implications associated with these two distinct subtypes of invasive breast cancer.